Pomalidomide 4'-PEG2-azide is primarily utilized in the development of targeted cancer therapies. Its structure allows for conjugation with other molecules, making it valuable in the creation of antibody-drug conjugates (ADCs). These ADCs are designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. The PEG2 linker enhances solubility and stability, while the azide group facilitates click chemistry for precise attachment to targeting antibodies or other biomolecules. This chemical is particularly significant in research focused on improving the efficacy and specificity of treatments for hematologic malignancies, such as multiple myeloma. Its application extends to the study of drug delivery systems, where it aids in optimizing pharmacokinetics and reducing off-target effects.